AnemiaPhase 3NCT00508131
Effectiveness of Iron-Fortified Milk on Iron Status and Anemia in Young Children in Mexico
A Phase 3 study testing Whole Cows Milk in people with Anemia and Iron Deficiency, run by Instituto Nacional de Salud Publica, Mexico at 1 site in Mexico.
Trial summary
Iron deficiency and anemia in infants and young children impair neurodevelopment. Efficacious interventions for reducing the prevalences of iron deficiency and anemia, under controlled conditions, are available. However, little information is published about the effectiveness of large-scale programs. Objective. Read more about this study
- Who is it for?
- Ages 12 to 30 monthsHealthy volunteers can take part
- Conditions the study is for
- Anemia, Iron Deficiency, Stunting
- What is being tested?
- Whole Cows Milk
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 798 participants
- Where
- 1 siteMexico
- Study dates
- May 2003to Jul 2004
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 30 months
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Healthy children 12-30 months of age who were beneficiaries of the program in the 12 milk distribution clusters
Who cannot join
- Children with severe anemia (Hb concentrations < 90 g/L)
Trial locations and contacts
1 site in 1 country.
About this study
Iron deficiency and anemia in infants and young children impair neurodevelopment. Efficacious interventions for reducing the prevalences of iron deficiency and anemia, under controlled conditions, are available. However, little information is published about the effectiveness of large-scale programs.
Objective. Assess the effectiveness on iron deficiency and anemia in young children of a large-scale program that provides iron fortified milk at a subsidized price to low income households. Design, Setting, and Sampling. A randomized effectiveness study in 12 milk distribution clusters randomly selected from 542 clusters in 4 States in Mexico. Selected clusters were randomly assigned to receive iron-fortified milk FM, N=7) or non-fortified milk (NFM, N=5). Over 95% program beneficiaries with children 12-30 mo of age in the 12 clusters (490 in FM and 275 in NFM) were enrolled in the FM and NFM interventions and participated in a baseline survey. 635 children (405 in FM and 230 in NFM) and 584 children (371 in FM and 213 in NFM) completed the 6 and 12-mo follow-up surveys, respectively. Intervention: A daily portion of FM contained 5.28 mg of iron, 48 mg of sodium ascorbate and other added micronutrients. The FM and NFM were distributed to beneficiaries at a subsidized price in Milk Distribution Centers in the 12 clusters.
Read more
Main outcome measures: Mild-to-moderate anemia (Hb: 90-109 g/L), mild anemia (Hb: 100-109 g/L), moderate anemia (Hb: 90-99 g/L),iron deficiency: Serum Ferritin (SF) <12 ug/L and soluble transferring receptors (sTfR) >6 mg/L.Serum Zinc deficiency (< 65ug/dL), and stunting (<2SD Height/Age.
Intervention effects at 6 and 12 moths were assessed using General Linear Mixed Models with three repeated measures.
Read the detailed description
Introduction. Iron deficiency anemia is the most common nutritional deficiency worldwide (1-3).Children less than 5 years are the most affected(4). Almost 24% of Mexican children 1-4 years of age are anemic and 52% iron deficient (5). The peak prevalence of anemia (38%) occurs in children 12-23 months of age (6). The prevalence is higher in low socioeconomic households (29 %) but remains high even in the highest quintile (17%). Anemia and iron deficiency in infants and young children are associated with adverse effects on neurodevelopment (7-12).
During several decades, the Mexican government has sold whole milk at subsidized prices to low income households with children 1-11 y of age through a federal program (Liconsa). In 2000 a decision was made to fortify the subsidized milk with iron, vitamin C and other micronutrients to contribute to the reduction of IDA and other micronutrient deficiencies. At that time, 4.2 million children 1-11 y old from low income families were beneficiaries of the program. There are very few examples of large scale public health interventions using iron fortified whole milk.
The effectiveness of interventions such as food fortification for reducing anemia and iron deficiency is often questioned (14) and little information is available on the effectiveness of these strategies implemented through large scale programs. Reliable evidence of the effectiveness of these strategies applied in large-scale programs is needed for planning interventions aimed at reducing the prevalence of iron and zinc deficiencies and anemia in children.This study aims to document the effectiveness on iron and zinc deficiencies,anemia and stunting, in young children of a large-scale program that distributes iron and zinc fortified milk to low income households at subsidized prices.
Methods The subsidized milk distribution program. The program was created in 1944 and is operated by a public organization (Liconsa)(15). It distributes whole milk at subsidized prices to families living in poverty. The milk distributed is intended mostly for children 1-11 y.
It is distributed in milk distribution centers throughout the Country as dry powder in 240 g sachets which yield two liters of fluid milk after hydration or as a 1 L container of fluid milk. Children receive the equivalent of 400 mL of fluid milk per day either in dry or fluid form for reducing the prevalence of iron deficiency anemia and other micronutrient deficiencies, through the fortification of the product with iron, zinc, vitamin C and micronutrients that were deficient in the diet of low income children in Mexico (5, 16). The program serves approximately 5 million individuals of which about 4.2 million are children <11 years and about 650,000 were children 12-30 months of age.
Design and sample. This randomized effectiveness trial on children 12-30 mo of age was conducted in 4 States of Central and Eastern Mexico. The randomized effectiveness trial was conducted in 12 milk distribution clusters (MDC) comprising periurban areas serving around 5000 beneficiaries with one or more milk distribution centers. These clusters were randomly selected from a universe of all MDC (n=542) in 4 States in central and eastern Mexico. The twelve clusters were randomly assigned to receive either fortified (n=7) or non-fortified (n=5) milk using a random numbers list. The clusters assigned to the non-fortified milk started receiving fortified milk at the end of the trial. The milk distributed to the participants in the trial was all in the dry form.
The duration of the trial was 12 months with a baseline survey and 2 follow-up surveys at approximately 6 and 12 months. The baseline study was conducted between May 28 and July 30, 2003. The 6 mo and 12 mo follow-up surveys were conducted between December 2003 and February 2004 and between June and July 2004, respectively. The mean time between the baseline and the 6 mo follow up was 5.4 mo and from the 6 to the 12 mo follow was 6.8 months.
The packages of fortified and non-fortified milk were undistinguishable, except for a color-coded band in the upper corner of the sachet. The color code was unknown to researchers, field workers, and program beneficiaries, and was not disclosed before data analysis. The iron and zinc content of the fortified milk was analyzed by our laboratory on samples of milk powder obtained from LICONSA at the beginning of the intervention.
Mothers or caretakers of children participating in the study received the same information and instructions provided regularly to all beneficiaries of the milk distribution program at the MDC. They were instructed how to reconstitute the milk powder and were encouraged to feed the selected children 400 mL, preferably at two separate times during the day (200 mL in the morning and 200 mL in the afternoon). Milk was bought and collected by each family on a weekly or bimonthly basis at the MDC. The portion of 400 mL of rehydrated fortified milk (FM) contained 5.28 mg of iron as ferrous gluconate, 48 mg of sodium ascorbate, 5.28 mg of zinc as zinc oxide and 36.2 mg of folic acid. The non-fortified milk (NFM) contained per 400 mL: 0.16 mg of iron, 1.6 mg of zinc and 6.8 mg of vitamin C. The micronutrient premix,purchased from DSM Nutritional Products (Herleen, The Nederland) was added to the powdered milk in the plant by the manufacturer (LICONSA, SA,Queretaro, Mexico) and 220 g units of the products were packed in metallic foil sachets.
A list of households with children 12-30 months of age (n=798) who were beneficiaries of the program in the 12 distribution clusters was provided by program officers at the beginning of the study. 510 of these children corresponded to the distribution clusters assigned to FM and 288 to the clusters assigned to NFM. The number of children in the FM clusters was larger for two reasons: more clusters were assigned to receive FM as a request from program officials who wished to minimize the number of children who would not receive the fortified milk immediately. In addition, some of the clusters randomly assigned to the fortified milk intervention served larger populations of beneficiaries. The parents or legal guardians of the 12-30 month old children were invited to participate and those who accepted signed an informed consent letter after a detailed explanation of the objectives, nature, and risks posed by the study. Prior to baseline measurements 33 children were excluded from the study (20 in the FM and 13 in the NFM groups) because they were either severely anemic (Hb concentrations < 90 g/L, n= 26) or refused to participate (n=7. Therefore, 765 children participated in the baseline measurements (490 in the FM and 275 in the NFM clusters). Between the baseline and the 6-mo follow-up measurements, 130 out of these children were lost to follow up for several reasons. Therefore 635 children completed 6 mo of follow up (n= 405 in the FM and 230 in the NFM groups). Between the 6-mo and the 12-mo follow-up measurements, 51 additional children were lost to follow up. Therefore 584 children completed 12 mo of follow up (n= 371 in the FM and 213 in the NFM groups).
For the 635 children who completed the 6 mo follow-up and the 584 who completed the 12 mo follow-up, hemoglobin concentrations (the main outcome of this study) as well as basic socio-demographic variables were available. iron status. The protocol was reviewed and approved by the Human Subjects and Ethics Committee of the National Public Health Institute, Mexico.
Data collection and processing. At the beginning of the study a questionnaire about the housing characteristics and possession of household goods was applied to the mother or child caretaker in all households. Hemoglobin concentrations were determined at baseline and 6 and 12 months after in capillary blood samples obtained by finger prick using a Portable Photometer Hemocue (HemoCue, Angelholm, Sweden)17, 18. Reliability of the photometers was assessed during fieldwork at the beginning and at the end of each working day. A three-level liquid quality control check (4C-ESControl, Beckman-Coulter, Miami Fla, USA), and the readings of a precalibrated reference cuvette included with the equipment were used for such purpose. The mean difference between duplicates was 0.3 ± 9.9 g/L, (P=0.36 for liquid quality control material and -0.24 ± 3.6 g/L, P= 0.27 for the reference cuvette). Venous blood samples were drawn from children at baseline and 6 and 12 mo after. Samples were centrifuged and serum was stored in color coded cryovials kept in liquid nitrogen until delivery to a central laboratory. Commercial kits were used to measure the SF concentrations, (Dade Behring Inc, Newark, DE 19714, U.S.A.) and sTfR (Dade Behring, Maburg, Germany) by ELISA. C reactive protein (CPR) was determined by nephelometry, using monoclonal antibodies (Behring Nephelometer 100 Analyzer, Behring Laboratories, Messer Grisheim Gmbh,Frankfurt, Germany. Serun zinc concentrations were mesured by Atomic Absorption spectrometry by a Analyst 300 model with graphite furnace(Perkin Elmer).
Length and weight were measured at baseline and at 6 and 12 mo after enrollment. Weight was measured to the nearest 10 g using an electronic scale (Tanita, Model 1583, Tokyo, Japan). Length was measured to the nearest millimeter using a locally made measuring board in children <24 months of age and standing height, using a stadimeter with precision of 1 mm (Dyna-Top, model E-1,Mexico City, Mexico) in children 24 months or older. The measurements were obtained using standard techniques (19, 20). The birth date was reported by the mother and corroborated in a large proportion of children using birth certificates. Length and weight data were transformed to z-scores by using the WHO/NCHS/CDC reference data (21).
To verify compliance a field worker visited the household every month, at the usual times of milk intake by the child, to verify the correct reconstitution of milk and to register the amount of milk consumed. During the same visit a questionnaire was applied regarding the intake of milk during the previous week.
A morbidity questionnaire was applied during the same visit. Feeding practices were assessed every 2 months through a food frequency questionnaire applied to the mother or caretaker.
Anemia was defined according to CDC recommendations as hemoglobin concentrations <110 g/L at sea level (18). Hemoglobin concentrations were adjusted for altitude following the equation proposed by Cohen and Haas (22). Iron deficiency was defined as SF <12 ug/L and as sTfR > 6 mg/L. SF indicates the level of storage iron and sTfR reflects tissue iron deficiency. Zinc deficiency was defined as by the IZnCG (<65ug/dL).
Using the information about housing characteristics and possession of household goods, an indicator of socioeconomic status (SES) was derived by the first component obtained by Principal Components Analysis (23) Only variables with factor loadings > 0.5 were maintained in the model. The variables included in the factor were: flooring material, ceiling material, availability of piped water,sanitary service, possession of refrigerator and washing machine as well as the number of electric appliances in the household: radio, TV, video player,telephone, and computer. The resulting standardized factor scores were divided into tertiles which were further used to construct SES status categories.
Statistical methods. Characteristics of study children at baseline and at 5 and 12 months and the socioeconomic status of their families were compared between intervention groups using t-test on continuous variables and Ji2 for categorical variables (24). Distributions which were not normal were transformed and were compared using t-test. When adequate transformations were not achieved, the Wilcoxon Rank-sum test was employed (24. Intervention effects at 6 and 12 moths were assessed using General Linear Mixed Models with three repeated measures (25). Dependent variables were the prevalences of anemia or iron deficiency by either SF or sTfR. The interaction term between intervention and indicator variables for 6 and 12 months were used as the measure of effects at 6 and 12 months adjusting for baseline measurements. All models were adjusted for cluster effects (Milk Distribution Centers) and covariates. Adjusted probabilities were obtained to illustrate effects in graphic form26. Main effects were considered statistically significant at p values < 0.05 and interactions at p values <0.10. Statistical analyses were carried out using STATA (version 9.0)
- Conditions
- Anemia, Iron Deficiency, Stunting
- Being tested
- Whole Cows Milk
- Keywords
- Milk fortification, Effectivness evaluation, Iron deficiency anemia, Stunting, Zinc deficiency
- Medical subject headings
- Anemia, Iron Deficiencies, Growth Disorders, Anemia, Iron-Deficiency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Whole Cows MilkOther
Also called Leche LICONSA (Liconsa, Mexico)
400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months.
| Study group | Role | What they receive |
|---|---|---|
| A | Active comparator | Milk fortified with, iron, zinc and vitamin C Receives: Other: Whole Cows Milk |
| B | Placebo comparator | Milk not fortified Receives: Other: Whole Cows Milk |
What is being measured
The primary outcome is the main question the study is designed to answer.
Anemia
Measured: 12 months
Iron deficiency
Measured: 12 months
Secondary outcomes (2)
Zinc deficiency
Measured: 12 months
Stunting
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jul 2007 (estimated)
- Study startMay 2003
- Study completionJul 2004
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for AnemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Double blind
- Enrolment
- 798 participants (actual)
Sponsor and investigators
- Lead sponsor
- Instituto Nacional de Salud Publica, Mexico
- Sponsor type
- University, hospital or other
- Investigators
- Salvador Villalpando, M. D., Ph.D, Principal investigator, Instituto Nacional de Salud Publica, MexicoTeresa Shamah, MSc, Study director, Instituto Nacional de Salud Publica, MexicoJuan A Rivera, MSc, Ph.D., Study chair, Instituto Nacional de Salud Publica, Mexico
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00508131
- Sponsor's protocol ID
- 1408svillalp
- Status last verified
- Jul 2007
- First submitted
- 26 Jul 2007
- Last updated
- 27 Jul 2007
- Results posted
- No
- Data monitoring committee
- No
Publications
Rivera JA, Shamah T, Villalpando S, Monterrubio E. Effectiveness of a large-scale iron-fortified milk distribution program on anemia and iron deficiency in low-income young children in Mexico. Am J Clin Nutr. 2010 Feb;91(2):431-9. doi: 10.3945/ajcn.2009.28104. Epub 2009 Dec 16.
PubMed 20016011
Study at a glance
From the registry record, last updated by the sponsor on 27 Jul 2007. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effectiveness of Iron-Fortified Milk on Iron Status and Anemia in Young Children in Mexico
- ClinicalTrials.gov ID
- NCT00508131
- Acronym / sponsor ID
- 1408svillalp
- Conditions
- Anemia, Iron Deficiency, Stunting
- Keywords
- Milk fortification, Effectivness evaluation, Iron deficiency anemia, Stunting, Zinc deficiency
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 798 participants (actual)
- Lead sponsor
- Instituto Nacional de Salud Publica, MexicoUniversity, hospital or other
- Study start
- May 2003
- Study completion
- Jul 2004 (actual)
- First posted
- 27 Jul 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Iron deficiency and anemia in infants and young children impair neurodevelopment. Efficacious interventions for reducing the prevalences of iron deficiency and anemia, under controlled conditions, are available. However, little information is published about the effectiveness of large-scale programs.
Objective. Assess the effectiveness on iron deficiency and anemia in young children of a large-scale program that provides iron fortified milk at a subsidized price to low income households. Design, Setting, and Sampling. A randomized effectiveness study in 12 milk distribution clusters randomly selected from 542 clusters in 4 States in Mexico. Selected clusters were randomly assigned to receive iron-fortified milk FM, N=7) or non-fortified milk (NFM, N=5). Over 95% program beneficiaries with children 12-30 mo of age in the 12 clusters (490 in FM and 275 in NFM) were enrolled in the FM and NFM interventions and participated in a baseline survey. 635 children (405 in FM and 230 in NFM) and 584 children (371 in FM and 213 in NFM) completed the 6 and 12-mo follow-up surveys, respectively. Intervention: A daily portion of FM contained 5.28 mg of iron, 48 mg of sodium ascorbate and other added micronutrients. The FM and NFM were distributed to beneficiaries at a subsidized price in Milk Distribution Centers in the 12 clusters.
Main outcome measures: Mild-to-moderate anemia (Hb: 90-109 g/L), mild anemia (Hb: 100-109 g/L), moderate anemia (Hb: 90-99 g/L),iron deficiency: Serum Ferritin (SF) <12 ug/L and soluble transferring receptors (sTfR) >6 mg/L.Serum Zinc deficiency (< 65ug/dL), and stunting (<2SD Height/Age.
Intervention effects at 6 and 12 moths were assessed using General Linear Mixed Models with three repeated measures.
Detailed description
Introduction. Iron deficiency anemia is the most common nutritional deficiency worldwide (1-3).Children less than 5 years are the most affected(4). Almost 24% of Mexican children 1-4 years of age are anemic and 52% iron deficient (5). The peak prevalence of anemia (38%) occurs in children 12-23 months of age (6). The prevalence is higher in low socioeconomic households (29 %) but remains high even in the highest quintile (17%). Anemia and iron deficiency in infants and young children are associated with adverse effects on neurodevelopment (7-12).
During several decades, the Mexican government has sold whole milk at subsidized prices to low income households with children 1-11 y of age through a federal program (Liconsa). In 2000 a decision was made to fortify the subsidized milk with iron, vitamin C and other micronutrients to contribute to the reduction of IDA and other micronutrient deficiencies. At that time, 4.2 million children 1-11 y old from low income families were beneficiaries of the program. There are very few examples of large scale public health interventions using iron fortified whole milk.
The effectiveness of interventions such as food fortification for reducing anemia and iron deficiency is often questioned (14) and little information is available on the effectiveness of these strategies implemented through large scale programs. Reliable evidence of the effectiveness of these strategies applied in large-scale programs is needed for planning interventions aimed at reducing the prevalence of iron and zinc deficiencies and anemia in children.This study aims to document the effectiveness on iron and zinc deficiencies,anemia and stunting, in young children of a large-scale program that distributes iron and zinc fortified milk to low income households at subsidized prices.
Methods The subsidized milk distribution program. The program was created in 1944 and is operated by a public organization (Liconsa)(15). It distributes whole milk at subsidized prices to families living in poverty. The milk distributed is intended mostly for children 1-11 y.
It is distributed in milk distribution centers throughout the Country as dry powder in 240 g sachets which yield two liters of fluid milk after hydration or as a 1 L container of fluid milk. Children receive the equivalent of 400 mL of fluid milk per day either in dry or fluid form for reducing the prevalence of iron deficiency anemia and other micronutrient deficiencies, through the fortification of the product with iron, zinc, vitamin C and micronutrients that were deficient in the diet of low income children in Mexico (5, 16). The program serves approximately 5 million individuals of which about 4.2 million are children <11 years and about 650,000 were children 12-30 months of age.
Design and sample. This randomized effectiveness trial on children 12-30 mo of age was conducted in 4 States of Central and Eastern Mexico. The randomized effectiveness trial was conducted in 12 milk distribution clusters (MDC) comprising periurban areas serving around 5000 beneficiaries with one or more milk distribution centers. These clusters were randomly selected from a universe of all MDC (n=542) in 4 States in central and eastern Mexico. The twelve clusters were randomly assigned to receive either fortified (n=7) or non-fortified (n=5) milk using a random numbers list. The clusters assigned to the non-fortified milk started receiving fortified milk at the end of the trial. The milk distributed to the participants in the trial was all in the dry form.
The duration of the trial was 12 months with a baseline survey and 2 follow-up surveys at approximately 6 and 12 months. The baseline study was conducted between May 28 and July 30, 2003. The 6 mo and 12 mo follow-up surveys were conducted between December 2003 and February 2004 and between June and July 2004, respectively. The mean time between the baseline and the 6 mo follow up was 5.4 mo and from the 6 to the 12 mo follow was 6.8 months.
The packages of fortified and non-fortified milk were undistinguishable, except for a color-coded band in the upper corner of the sachet. The color code was unknown to researchers, field workers, and program beneficiaries, and was not disclosed before data analysis. The iron and zinc content of the fortified milk was analyzed by our laboratory on samples of milk powder obtained from LICONSA at the beginning of the intervention.
Mothers or caretakers of children participating in the study received the same information and instructions provided regularly to all beneficiaries of the milk distribution program at the MDC. They were instructed how to reconstitute the milk powder and were encouraged to feed the selected children 400 mL, preferably at two separate times during the day (200 mL in the morning and 200 mL in the afternoon). Milk was bought and collected by each family on a weekly or bimonthly basis at the MDC. The portion of 400 mL of rehydrated fortified milk (FM) contained 5.28 mg of iron as ferrous gluconate, 48 mg of sodium ascorbate, 5.28 mg of zinc as zinc oxide and 36.2 mg of folic acid. The non-fortified milk (NFM) contained per 400 mL: 0.16 mg of iron, 1.6 mg of zinc and 6.8 mg of vitamin C. The micronutrient premix,purchased from DSM Nutritional Products (Herleen, The Nederland) was added to the powdered milk in the plant by the manufacturer (LICONSA, SA,Queretaro, Mexico) and 220 g units of the products were packed in metallic foil sachets.
A list of households with children 12-30 months of age (n=798) who were beneficiaries of the program in the 12 distribution clusters was provided by program officers at the beginning of the study. 510 of these children corresponded to the distribution clusters assigned to FM and 288 to the clusters assigned to NFM. The number of children in the FM clusters was larger for two reasons: more clusters were assigned to receive FM as a request from program officials who wished to minimize the number of children who would not receive the fortified milk immediately. In addition, some of the clusters randomly assigned to the fortified milk intervention served larger populations of beneficiaries. The parents or legal guardians of the 12-30 month old children were invited to participate and those who accepted signed an informed consent letter after a detailed explanation of the objectives, nature, and risks posed by the study. Prior to baseline measurements 33 children were excluded from the study (20 in the FM and 13 in the NFM groups) because they were either severely anemic (Hb concentrations < 90 g/L, n= 26) or refused to participate (n=7. Therefore, 765 children participated in the baseline measurements (490 in the FM and 275 in the NFM clusters). Between the baseline and the 6-mo follow-up measurements, 130 out of these children were lost to follow up for several reasons. Therefore 635 children completed 6 mo of follow up (n= 405 in the FM and 230 in the NFM groups). Between the 6-mo and the 12-mo follow-up measurements, 51 additional children were lost to follow up. Therefore 584 children completed 12 mo of follow up (n= 371 in the FM and 213 in the NFM groups).
For the 635 children who completed the 6 mo follow-up and the 584 who completed the 12 mo follow-up, hemoglobin concentrations (the main outcome of this study) as well as basic socio-demographic variables were available. iron status. The protocol was reviewed and approved by the Human Subjects and Ethics Committee of the National Public Health Institute, Mexico.
Data collection and processing. At the beginning of the study a questionnaire about the housing characteristics and possession of household goods was applied to the mother or child caretaker in all households. Hemoglobin concentrations were determined at baseline and 6 and 12 months after in capillary blood samples obtained by finger prick using a Portable Photometer Hemocue (HemoCue, Angelholm, Sweden)17, 18. Reliability of the photometers was assessed during fieldwork at the beginning and at the end of each working day. A three-level liquid quality control check (4C-ESControl, Beckman-Coulter, Miami Fla, USA), and the readings of a precalibrated reference cuvette included with the equipment were used for such purpose. The mean difference between duplicates was 0.3 ± 9.9 g/L, (P=0.36 for liquid quality control material and -0.24 ± 3.6 g/L, P= 0.27 for the reference cuvette). Venous blood samples were drawn from children at baseline and 6 and 12 mo after. Samples were centrifuged and serum was stored in color coded cryovials kept in liquid nitrogen until delivery to a central laboratory. Commercial kits were used to measure the SF concentrations, (Dade Behring Inc, Newark, DE 19714, U.S.A.) and sTfR (Dade Behring, Maburg, Germany) by ELISA. C reactive protein (CPR) was determined by nephelometry, using monoclonal antibodies (Behring Nephelometer 100 Analyzer, Behring Laboratories, Messer Grisheim Gmbh,Frankfurt, Germany. Serun zinc concentrations were mesured by Atomic Absorption spectrometry by a Analyst 300 model with graphite furnace(Perkin Elmer).
Length and weight were measured at baseline and at 6 and 12 mo after enrollment. Weight was measured to the nearest 10 g using an electronic scale (Tanita, Model 1583, Tokyo, Japan). Length was measured to the nearest millimeter using a locally made measuring board in children <24 months of age and standing height, using a stadimeter with precision of 1 mm (Dyna-Top, model E-1,Mexico City, Mexico) in children 24 months or older. The measurements were obtained using standard techniques (19, 20). The birth date was reported by the mother and corroborated in a large proportion of children using birth certificates. Length and weight data were transformed to z-scores by using the WHO/NCHS/CDC reference data (21).
To verify compliance a field worker visited the household every month, at the usual times of milk intake by the child, to verify the correct reconstitution of milk and to register the amount of milk consumed. During the same visit a questionnaire was applied regarding the intake of milk during the previous week.
A morbidity questionnaire was applied during the same visit. Feeding practices were assessed every 2 months through a food frequency questionnaire applied to the mother or caretaker.
Anemia was defined according to CDC recommendations as hemoglobin concentrations <110 g/L at sea level (18). Hemoglobin concentrations were adjusted for altitude following the equation proposed by Cohen and Haas (22). Iron deficiency was defined as SF <12 ug/L and as sTfR > 6 mg/L. SF indicates the level of storage iron and sTfR reflects tissue iron deficiency. Zinc deficiency was defined as by the IZnCG (<65ug/dL).
Using the information about housing characteristics and possession of household goods, an indicator of socioeconomic status (SES) was derived by the first component obtained by Principal Components Analysis (23) Only variables with factor loadings > 0.5 were maintained in the model. The variables included in the factor were: flooring material, ceiling material, availability of piped water,sanitary service, possession of refrigerator and washing machine as well as the number of electric appliances in the household: radio, TV, video player,telephone, and computer. The resulting standardized factor scores were divided into tertiles which were further used to construct SES status categories.
Statistical methods. Characteristics of study children at baseline and at 5 and 12 months and the socioeconomic status of their families were compared between intervention groups using t-test on continuous variables and Ji2 for categorical variables (24). Distributions which were not normal were transformed and were compared using t-test. When adequate transformations were not achieved, the Wilcoxon Rank-sum test was employed (24. Intervention effects at 6 and 12 moths were assessed using General Linear Mixed Models with three repeated measures (25). Dependent variables were the prevalences of anemia or iron deficiency by either SF or sTfR. The interaction term between intervention and indicator variables for 6 and 12 months were used as the measure of effects at 6 and 12 months adjusting for baseline measurements. All models were adjusted for cluster effects (Milk Distribution Centers) and covariates. Adjusted probabilities were obtained to illustrate effects in graphic form26. Main effects were considered statistically significant at p values < 0.05 and interactions at p values <0.10. Statistical analyses were carried out using STATA (version 9.0)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Double blind
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| A | Active comparator | Other: Whole Cows MilkMilk fortified with, iron, zinc and vitamin C |
| B | Placebo comparator | Other: Whole Cows MilkMilk not fortified |
Who may qualify
- Ages
- 12 to 30 months
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- Healthy children 12-30 months of age who were beneficiaries of the program in the 12 milk distribution clusters
Key exclusion criteria (1 listed)
- Children with severe anemia (Hb concentrations < 90 g/L)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Whole Cows MilkAlso: Leche LICONSA (Liconsa, Mexico)400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months. | Other | A, B |
Primary outcome
Anemia
Time frame: 12 months
Iron deficiency
Time frame: 12 months
2 secondary outcomes
Zinc deficiency
Time frame: 12 months
Stunting
Time frame: 12 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jul 2007.
- Derived from this study: PubMed 20016011Rivera JA, Shamah T, Villalpando S, Monterrubio E. Effectiveness of a large-scale iron-fortified milk distribution program on anemia and iron deficiency in low-income young children in Mexico. Am J Clin Nutr. 2010 Feb;91(2):431-9. doi: 10.3945/ajcn.2009.28104. Epub 2009 Dec 16.
Related trials for Anemia
RecruitingPhase 1/2
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
Aplastic Anemia, Refractory
Active, not recruitingPhase 1
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
Autoimmune Hemolytic Anemia, Anti-CD19 STAR T-cell Therapy
Not yet recruitingObservational study
Systematic Intraoperative Cell Salvage in On-Pump Cardiac Surgery Within a Mature Patient Blood Management Programme
Cardiac Surgical Procedures, Blood Transfusion
RecruitingPhase 1/2
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Myelodysplastic Syndromes
RecruitingObservational study
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Fanconi Anemia, Inherited Bone Marrow Failure Syndrome
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Salvador Villalpando, M. D., Ph.D principal investigator
Instituto Nacional de Salud Publica, Mexico
Teresa Shamah, MSc study director
Instituto Nacional de Salud Publica, Mexico
Juan A Rivera, MSc, Ph.D. study chair
Instituto Nacional de Salud Publica, Mexico
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Whole Cows Milk in people with Anemia and Iron Deficiency, run by Instituto Nacional de Salud Publica, Mexico at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Jul 2007. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Anemia (time frame: 12 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00508131, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jul 2007.